US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

18.82

-0.1700-0.90%

Volume:130.78K

Turnover:2.46M

Market Cap:2.46B

PE:10.65

High:18.96

Open:18.75

Low:18.66

Close:18.99

52wk High:22.24

52wk Low:14.34

Shares:130.62M

Float Shares:126.13M

Volume Ratio:0.56

T/O Rate:0.10%

Dividend:0.96

Dividend Rate:5.10%

EPS(TTM):1.77

EPS(LYR):1.05

ROE:8.78%

ROA:0.95%

PB:0.91

PE(LYR):17.87

Loading ...

Overview Company News Filings

Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress

Roche Targets Top Spot In Weight Loss Drug Market

Lion Copper and Gold Files PFS for Yerington Project, Boosting U.S. Copper Production Potential

Zeotech’s AusPozz Project PFS Highlights Potential and Challenges

Provident Financial Services Inc. EVP, CRO James A. Christy Reports Disposal of Common Shares

Zeotech Finalises $204 Million Kaolin Offtake Agreement with Chinese Trading Giant Jiangsu MSI

Stonegate Capital Partners Begins Coverage on Provident Financial Services Inc

Director John Pugliese Reports Disposal of Common Shares in Provident Financial Services Inc

Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig

Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer

The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration

Centerra Gold’s Mount Milligan PFS Outlines Mine Life to 2045, Delivering Growth with a Fully Funded, Disciplined $186 Million Growth Capital Plan

MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Press Release: Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy

Benzinga_recent_news

YY Group Announces Highlights of the Company’s Preliminary First Half 2025 Results

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

McEwen Reports Attractive Gold Intercepts at Grey Fox; Results Support Resource Growth Ahead of Upcoming Resource Estimate; Gibson: 10.1 g/t Gold Over 5.8 m (25GF-1597) and 10.4 g/t Gold Over 5.6 m (25GF-1564), GFS: 4.8 g/t Gold Over 14.9 m (25GF-1575)

BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients

Benzinga_recent_news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PFS/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":18.82,"timestamp":1761670369927,"preClose":18.99,"halted":0,"volume":130781,"delay":0,"floatShares":126131374,"shares":130624153,"eps":1.766905,"marketStatus":"Trading","change":-0.17,"latestTime":"10-28 12:52:50 EDT","open":18.745,"high":18.96,"low":18.66,"amount":2460056.392843,"amplitude":0.015798,"askPrice":18.84,"askSize":18,"bidPrice":18.82,"bidSize":157,"shortable":3,"etf":0,"ttmEps":1.766905,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1761681600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":18.99,"dividendRate":0.05101,"preHourTrading":{"tag":"盘前","latestPrice":18.9,"preClose":18.99,"latestTime":"08:53 EDT","volume":75,"amount":1417.5,"timestamp":1761656031342},"postHourTrading":{"tag":"盘后","latestPrice":18.99,"preClose":18.99,"latestTime":"16:16 EDT","volume":21205,"amount":402680.41,"timestamp":1761596160507},"volumeRatio":0.56227,"impliedVol":0.1839,"impliedVolPercentile":0.372},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126131374,"roa":"0.95%","roe":"8.78%","lyrEps":1.053397,"volumeRatio":0.56227,"shares":130624153,"dividePrice":0.96,"high":18.96,"amplitude":0.015798,"preClose":18.99,"low":18.66,"week52Low":14.335,"pbRate":"0.91","psRate":"2.99","week52High":22.24,"institutionHeld":0.6972,"latestPrice":18.82,"committee":0.794286,"eps":1.766905,"divideRate":0.05101,"volume":130781,"delay":0,"ttmEps":1.766905,"open":18.745,"prevYearClose":18.87,"prevWeekClose":18.99,"prevMonthClose":19.28,"prevQuarterClose":19.28,"fiveDayClose":18.68,"twentyDayClose":19.28,"sixtyDayClose":18.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2025-10-29","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/09","expectedEps":0.55,"defaultRemindTime":1761768000000,"name":null,"time":"Post Market","dateTimestamp":1761710400000,"actualEps":null},{"date":"2025-08-15","symbol":"PFS","amount":0.24,"announcedDate":"2025-07-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-15","defaultRemindTime":1755264600000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-08-15","currency":"USD","dateTimestamp":1755230400000,"payDate":"2025-08-29"},{"market":"US","date":"2025-07-24","symbol":"PFS","fiscalQuarterEnding":"2025/06","expectedEps":0.5,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753329600000,"reportTimeType":"pre","actualEps":0.55},{"date":"2025-05-16","symbol":"PFS","amount":0.24,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-16","defaultRemindTime":1747402200000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-16","currency":"USD","dateTimestamp":1747368000000,"payDate":"2025-05-30"},{"date":"2025-04-24","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.47,"defaultRemindTime":1745524800000,"name":null,"time":"Post Market","dateTimestamp":1745467200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2015-11-10","recordDate":"2015-11-13","paymentDate":"2015-11-27","value":0.17,"currency":"USD"},{"executeDate":"2016-02-10","recordDate":"2016-02-12","paymentDate":"2016-02-26","value":0.17,"currency":"USD"},{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"},{"executeDate":"2016-08-11","recordDate":"2016-08-15","paymentDate":"2016-08-31","value":0.18,"currency":"USD"},{"executeDate":"2016-11-10","recordDate":"2016-11-15","paymentDate":"2016-11-30","value":0.18,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1751169600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2025-10-24","current":10.747607,"percent":0.410585,"low":6.410614,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"high":33.979783,"avg":13.530778,"sd":6.3925,"marketCap":2419159313},"quantilePoints":[{"date":"2020-10-30","current":10.595048,"twenty":12.75677,"median":16.971439,"eighty":18.91343,"marketCap":872343311},{"date":"2020-11-06","current":10.696549,"twenty":12.723452,"median":16.947615,"eighty":18.891695,"marketCap":880700321},{"date":"2020-11-13","current":13.674488,"twenty":12.723452,"median":16.898923,"eighty":18.890505,"marketCap":1125888942},{"date":"2020-11-20","current":14.639195,"twenty":12.723452,"median":16.877422,"eighty":18.890505,"marketCap":1205318094},{"date":"2020-11-27","current":15.191794,"twenty":12.723452,"median":16.856678,"eighty":18.890505,"marketCap":1250816345},{"date":"2020-12-04","current":16.053474,"twenty":12.723452,"median":16.820466,"eighty":18.876273,"marketCap":1321762772},{"date":"2020-12-11","current":16.072206,"twenty":12.723452,"median":16.79439,"eighty":18.876273,"marketCap":1323305085},{"date":"2020-12-18","current":16.222063,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1335643594},{"date":"2020-12-24","current":16.718466,"twenty":12.723452,"median":16.730308,"eighty":18.876273,"marketCap":1376514905},{"date":"2020-12-31","current":16.821493,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1384997630},{"date":"2021-01-08","current":18.095281,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1489874956},{"date":"2021-01-15","current":17.992254,"twenty":12.723452,"median":16.744122,"eighty":18.876273,"marketCap":1481392232},{"date":"2021-01-22","current":18.142111,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1493730740},{"date":"2021-01-29","current":14.720538,"twenty":12.723452,"median":16.78893,"eighty":18.876273,"marketCap":1427170886},{"date":"2021-02-05","current":15.094115,"twenty":12.723452,"median":16.757917,"eighty":18.876273,"marketCap":1463389586},{"date":"2021-02-12","current":15.571023,"twenty":12.723452,"median":16.755695,"eighty":18.876273,"marketCap":1509626224},{"date":"2021-02-19","current":15.626662,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1515020498},{"date":"2021-02-26","current":16.079724,"twenty":12.723452,"median":16.714233,"eighty":18.876273,"marketCap":1558945304},{"date":"2021-03-05","current":17.794179,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1725163471},{"date":"2021-03-12","current":18.789768,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1821686827},{"date":"2021-03-19","current":18.215526,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1766013442},{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":15.595237,"twenty":8.579877,"median":10.368229,"eighty":12.928956,"marketCap":1870555147},{"date":"2024-06-07","current":14.804645,"twenty":8.579877,"median":10.368229,"eighty":12.944965,"marketCap":1775728393},{"date":"2024-06-14","current":14.479745,"twenty":8.579877,"median":10.368229,"eighty":12.974084,"marketCap":1736758494},{"date":"2024-06-21","current":14.609705,"twenty":8.578848,"median":10.365511,"eighty":13.001042,"marketCap":1752346453},{"date":"2024-06-28","current":15.541087,"twenty":8.578848,"median":10.365511,"eighty":13.028149,"marketCap":1864060164},{"date":"2024-07-05","current":15.400297,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":1847173207},{"date":"2024-07-12","current":17.403852,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":2087487584},{"date":"2024-07-19","current":19.212466,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2304420021},{"date":"2024-07-26","current":32.346496,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2473083727},{"date":"2024-08-02","current":29.436843,"twenty":8.578848,"median":10.365511,"eighty":13.071794,"marketCap":2250623276},{"date":"2024-08-09","current":28.842709,"twenty":8.578848,"median":10.365511,"eighty":13.113823,"marketCap":2205198173},{"date":"2024-08-16","current":30.822445,"twenty":8.578848,"median":10.365511,"eighty":13.134508,"marketCap":2356560887},{"date":"2024-08-23","current":32.631515,"twenty":8.578848,"median":10.365511,"eighty":13.176313,"marketCap":2494875092},{"date":"2024-08-30","current":32.546181,"twenty":8.578848,"median":10.365511,"eighty":13.215944,"marketCap":2488350837},{"date":"2024-09-06","current":31.197913,"twenty":8.578848,"median":10.365511,"eighty":13.228055,"marketCap":2385267609},{"date":"2024-09-13","current":31.300313,"twenty":8.578848,"median":10.365511,"eighty":13.30073,"marketCap":2393096715},{"date":"2024-09-20","current":32.187781,"twenty":8.578848,"median":10.365511,"eighty":13.316627,"marketCap":2460948967},{"date":"2024-09-27","current":31.283246,"twenty":8.578848,"median":10.365511,"eighty":13.405115,"marketCap":2391791864},{"date":"2024-10-04","current":30.429912,"twenty":8.578848,"median":10.365511,"eighty":13.64376,"marketCap":2326549315},{"date":"2024-10-11","current":32.136581,"twenty":8.578848,"median":10.365511,"eighty":13.888037,"marketCap":2457034414},{"date":"2024-10-18","current":33.314182,"twenty":8.578848,"median":10.365511,"eighty":14.144229,"marketCap":2547069132},{"date":"2024-10-25","current":31.88058,"twenty":8.578848,"median":10.365511,"eighty":14.323115,"marketCap":2437461649},{"date":"2024-11-01","current":26.079311,"twenty":8.578848,"median":10.365511,"eighty":14.468915,"marketCap":2459644116},{"date":"2024-11-08","current":29.303632,"twenty":8.578848,"median":10.365511,"eighty":14.501405,"marketCap":2763742765},{"date":"2024-11-15","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.577215,"marketCap":2792450197},{"date":"2024-11-22","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.642195,"marketCap":2792450197},{"date":"2024-11-29","current":29.220619,"twenty":8.578848,"median":10.365511,"eighty":14.720538,"marketCap":2755913466},{"date":"2024-12-06","current":28.72254,"twenty":8.578848,"median":10.365511,"eighty":14.772155,"marketCap":2708937668},{"date":"2024-12-13","current":28.16912,"twenty":8.578848,"median":10.365511,"eighty":14.811522,"marketCap":2656742337},{"date":"2024-12-20","current":26.370502,"twenty":8.578848,"median":10.365511,"eighty":14.879507,"marketCap":2487107512},{"date":"2024-12-27","current":26.107627,"twenty":8.578848,"median":10.365511,"eighty":14.930682,"marketCap":2462314730},{"date":"2025-01-03","current":26.19064,"twenty":8.578848,"median":10.365511,"eighty":15.008136,"marketCap":2470144030},{"date":"2025-01-10","current":24.945443,"twenty":8.578722,"median":10.36461,"eighty":15.045075,"marketCap":2352704535},{"date":"2025-01-17","current":26.730225,"twenty":8.578722,"median":10.36461,"eighty":15.087294,"marketCap":2521034477},{"date":"2025-01-24","current":26.232147,"twenty":8.578722,"median":10.36461,"eighty":15.170193,"marketCap":2474058679},{"date":"2025-01-31","current":20.975271,"twenty":8.578722,"median":10.36461,"eighty":15.27162,"marketCap":2423168232},{"date":"2025-02-07","current":21.686872,"twenty":8.578722,"median":10.36461,"eighty":15.43113,"marketCap":2505375878},{"date":"2025-02-14","current":21.065633,"twenty":8.578722,"median":10.36461,"eighty":15.506431,"marketCap":2433607298},{"date":"2025-02-21","current":20.489576,"twenty":8.578722,"median":10.36461,"eighty":15.601522,"marketCap":2367058251},{"date":"2025-02-28","current":20.614008,"twenty":8.578722,"median":10.36461,"eighty":15.733365,"marketCap":2381433247},{"date":"2025-03-07","current":19.427996,"twenty":8.578596,"median":10.36371,"eighty":15.909803,"marketCap":2244419279},{"date":"2025-03-14","current":19.373214,"twenty":8.58723,"median":10.384564,"eighty":16.110435,"marketCap":2238090520},{"date":"2025-03-21","current":19.113398,"twenty":8.626133,"median":10.390798,"eighty":16.250162,"marketCap":2208075312},{"date":"2025-03-28","current":19.282843,"twenty":8.679674,"median":10.422436,"eighty":16.324736,"marketCap":2227650448},{"date":"2025-04-04","current":17.498022,"twenty":8.697705,"median":10.433885,"eighty":16.538637,"marketCap":2021459018},{"date":"2025-04-11","current":16.594315,"twenty":8.729831,"median":10.450581,"eighty":16.720339,"marketCap":1917058294},{"date":"2025-04-17","current":17.498022,"twenty":8.74788,"median":10.472646,"eighty":16.838352,"marketCap":2021459018},{"date":"2025-04-25","current":14.654875,"twenty":8.784492,"median":10.48224,"eighty":16.926427,"marketCap":2161169063},{"date":"2025-05-02","current":15.142189,"twenty":8.798752,"median":10.513034,"eighty":16.926427,"marketCap":2233033814},{"date":"2025-05-09","current":15.159534,"twenty":8.804878,"median":10.526765,"eighty":16.926427,"marketCap":2235591607},{"date":"2025-05-16","current":15.505075,"twenty":8.82909,"median":10.533858,"eighty":16.926427,"marketCap":2286548985},{"date":"2025-05-23","current":14.787412,"twenty":8.855843,"median":10.556785,"eighty":16.926427,"marketCap":2180714431},{"date":"2025-05-30","current":14.884872,"twenty":8.8606,"median":10.572534,"eighty":16.926427,"marketCap":2195087025},{"date":"2025-06-06","current":14.619071,"twenty":8.875633,"median":10.60779,"eighty":16.926427,"marketCap":2155889043},{"date":"2025-06-13","current":15.000053,"twenty":8.887975,"median":10.619572,"eighty":16.926427,"marketCap":2212072818},{"date":"2025-06-20","current":14.30011,"twenty":8.911603,"median":10.626285,"eighty":16.928687,"marketCap":2108851463},{"date":"2025-06-27","current":15.850617,"twenty":8.946056,"median":10.641658,"eighty":16.928687,"marketCap":2337506362},{"date":"2025-07-03","current":16.710041,"twenty":8.946056,"median":10.65175,"eighty":16.928687,"marketCap":2464246506},{"date":"2025-07-11","current":16.648021,"twenty":8.954399,"median":10.683931,"eighty":16.928687,"marketCap":2455100310},{"date":"2025-07-18","current":16.4974,"twenty":8.954399,"median":10.718159,"eighty":16.928687,"marketCap":2432888120},{"date":"2025-07-25","current":10.379214,"twenty":8.954399,"median":10.725223,"eighty":16.928687,"marketCap":2396954859},{"date":"2025-08-01","current":10.305683,"twenty":8.954399,"median":10.733069,"eighty":16.928687,"marketCap":2379973707},{"date":"2025-08-08","current":10.124683,"twenty":8.954399,"median":10.733069,"eighty":16.928687,"marketCap":2338173949},{"date":"2025-08-15","current":10.899581,"twenty":8.954399,"median":10.730998,"eighty":16.928687,"marketCap":2517127428},{"date":"2025-08-22","current":10.633738,"twenty":8.954399,"median":10.730998,"eighty":16.928687,"marketCap":2455734076},{"date":"2025-08-29","current":11.255924,"twenty":8.954399,"median":10.756738,"eighty":16.928687,"marketCap":2599420644},{"date":"2025-09-05","current":11.380362,"twenty":8.954068,"median":10.786944,"eighty":16.930946,"marketCap":2628157958},{"date":"2025-09-12","current":11.312487,"twenty":8.954399,"median":10.806309,"eighty":16.928687,"marketCap":2612483060},{"date":"2025-09-19","current":11.493487,"twenty":8.954399,"median":10.823106,"eighty":16.928687,"marketCap":2654282788},{"date":"2025-09-26","current":11.0523,"twenty":8.984755,"median":10.848771,"eighty":16.928687,"marketCap":2552395949},{"date":"2025-10-03","current":11.018362,"twenty":8.984755,"median":10.865282,"eighty":16.928687,"marketCap":2544558500},{"date":"2025-10-10","current":10.876956,"twenty":8.984755,"median":10.902195,"eighty":16.928687,"marketCap":2511902462},{"date":"2025-10-17","current":10.113363,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2335559855},{"date":"2025-10-24","current":10.475363,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2419159313}],"updateTime":1761633436379},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2569795692","title":"Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2569795692","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569795692?lang=en_us&edition=fundamental","pubTime":"2025-09-23 17:03","pubTimestamp":1758618180,"startTime":"0","endTime":"0","summary":"CHENGDU, China, Sept. 23, 2025 /PRNewswire/ --The 2025 European Society for Medical Oncology  Congress will take place in Berlin, Germany, from October 17 to 21. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  will present results from multiple clinical studies at the congress, including data from its TROP2 ADC sacituzumab tirumotecan , HER2 ADC A166 , and CLDN18.2 ADC SKB315. Among these, two Phase III clinical studies of sac-TMT were selected for the Latest Breakthrough Abstracts  and presented as oral reports, including one featured in the Presidential Symposium; one Phase III clinical study of A166 was selected for LBA and presented as oral report.Abstract titles of these studies have been published on the official website of ESMO. The study results to be presented include:. Title:Sacituzumab tirumotecan  in Participants  with Previously Treated, Advanced KRAS-Mutant NSCLC: Results from Cohort 5d of the SKB264-II-08 StudyPresentation Type: PosterPresentation #: 1945PDate and Ses","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2650617/logo_kelun_Biotech_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/kelun-biotech-to-present-results-from-multiple-clinical-studies-at-the-2025-esmo-congress-302564241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","LU0265550359.USD","DAR","IE000M9KFDE8.USD","LU1571399168.USD","LU1929549753.HKD","LU1989772923.USD","LU2308191902.HKD","LU0211331839.USD","LU0098860793.USD","LU1430594728.SGD","BK4534","BLZ.SI","LU0106261372.USD","LU0203345920.USD","IE00B1BXHZ80.USD","BK4189","BC","IE00B2B36J28.USD","LU1974910355.USD","IE0002141913.USD","CDE","LU1037948541.HKD","ADC.AU","LU1979443071.USD","LU0265550946.USD","MSD","LU1223082519.USD","LU0320765646.SGD","ADC","LU1934455863.HKD","LU2023250843.SGD","SG9999001176.SGD","PFS","LU1983299246.USD","LU2461242641.AUD","LU1069347547.HKD","002422","BK4190","CDE.AU","LU1223082196.USD","IE00B4R5TH58.HKD","LU1066053197.SGD","LU0320765489.SGD","BK4195","LU1116320901.HKD","LU1162221912.USD","LU1941712264.USD","MRK"],"gpt_icon":0},{"id":"2569326577","title":"Roche Targets Top Spot In Weight Loss Drug Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2569326577","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569326577?lang=en_us&edition=fundamental","pubTime":"2025-09-23 02:04","pubTimestamp":1758564240,"startTime":"0","endTime":"0","summary":"Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/22/Roche.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/22/Roche.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/large-cap/25/09/47801165/roche-targets-top-spot-in-weight-loss-drug-market","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/25/09/47801165/roche-targets-top-spot-in-weight-loss-drug-market","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["PFS","OS","BK4195","BK4097","BK4211"],"gpt_icon":0},{"id":"2568820842","title":"Lion Copper and Gold Files PFS for Yerington Project, Boosting U.S. Copper Production Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2568820842","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568820842?lang=en_us&edition=fundamental","pubTime":"2025-09-19 08:38","pubTimestamp":1758242319,"startTime":"0","endTime":"0","summary":"Lion Copper and Gold ( ($TSE:LEO) ) has shared an announcement. Lion Copper and Gold Corp. has announced the filing of a Pre-Feasibility Study (PFS...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lion-copper-and-gold-files-pfs-for-yerington-project-boosting-u-s-copper-production-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lion-copper-and-gold-files-pfs-for-yerington-project-boosting-u-s-copper-production-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","IAU","GCmain","HGmain","GDX","159934","1OZmain","MGCmain","SGUmain","518880","SGCmain","DUST","NUGT","PFS","MHGmain","BK4211","QCmain"],"gpt_icon":0},{"id":"2567121739","title":"Zeotech’s AusPozz Project PFS Highlights Potential and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2567121739","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567121739?lang=en_us&edition=fundamental","pubTime":"2025-09-16 09:09","pubTimestamp":1757984967,"startTime":"0","endTime":"0","summary":"An update from Zeotech Limited ( ($AU:ZEO) ) is now available. Zeotech Limited has released a Preliminary Feasibility Study (PFS) for its AusPozz P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zeotechs-auspozz-project-pfs-highlights-potential-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zeotechs-auspozz-project-pfs-highlights-potential-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2567173148","title":"Provident Financial Services Inc. EVP, CRO James A. Christy Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2567173148","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567173148?lang=en_us&edition=fundamental","pubTime":"2025-09-15 22:57","pubTimestamp":1757948267,"startTime":"0","endTime":"0","summary":"James A. Christy, EVP and CRO of Provident Bank, reported a disposal of common shares of Provident Financial Services Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provident Financial Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDLbR5Wmz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2567160069","title":"Zeotech Finalises $204 Million Kaolin Offtake Agreement with Chinese Trading Giant Jiangsu MSI","url":"https://stock-news.laohu8.com/highlight/detail?id=2567160069","media":"Small Caps","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567160069?lang=en_us&edition=fundamental","pubTime":"2025-09-15 12:52","pubTimestamp":1757911943,"startTime":"0","endTime":"0","summary":"Zeotech  has signed a kaolin offtake agreement worth as much as $204 million with Chinese trading house Jiangsu Mineral Sources International , which has committed to receive 950,0000 tonnes of direct shipping ore  products over the initial term of five years.This number is significantly higher the total product volumes forecast in Zeotech’s recently released preliminary feasibility study  for the AusPozz project.The agreement follows the two companies signing a binding offtake term sheet in August that set out the core terms of the agreement, and a non-binding Memorandum of Understanding in May that established the framework for subsequent negotiations.Chief executive officer James Marsh said the agreement represents Australia’s largest kaolin offtake deal—delivering an average net margin of more than 45% across the initial term, based on committed volumes and Year 1 pricing.“Partnering with MSI, one of the world’s leading bulk raw material trading companies, represents a major commer","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Zeotech-ASX-ZEO-Kaolin-Offtake-Agreement-Chinese-Trading-Giant-Jiangsu-MSI.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Zeotech-ASX-ZEO-Kaolin-Offtake-Agreement-Chinese-Trading-Giant-Jiangsu-MSI.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/zeotech-finalises-kaolin-offtake-agreement-chinese-trading-giant-jiangsu-msi/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/zeotech-finalises-kaolin-offtake-agreement-chinese-trading-giant-jiangsu-msi/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["LU2125909916.SGD","LU2065171311.SGD","IE00B3S45H60.SGD","LU2065171402.SGD","LU2473716301.USD","LU2023250504.SGD","BK7031","LU2065170008.USD","BK7095","IE00B775SV38.USD","LU1791710582.SGD","LU2506951875.HKD","LU0823417653.USD","LU2322448957.HKD","BK4195","LU2023250843.SGD","LOM.AU","BK4159","LU2237443622.USD","LU2237443978.SGD","BK4211","LU0528227936.USD","LU2065169927.USD","LU2506951958.HKD","LU2237443382.USD","LU2506952170.USD","ZEO.AU","LU1791710400.SGD","LU2272731782.SGD","LU0823417737.USD","PFS","BK7116","LU0950375773.USD","BK4020","BK4585","LU1917777945.USD","LU2272731865.HKD","LU0354030511.USD","LU2272731600.USD","LU2125909759.SGD","LU2106854487.HKD","GPC","LU2506952097.USD","LU1992135399.USD","MSI","LU1974910355.USD","MSI.AU","LU2237443549.SGD","BK7509","LU2247934214.USD"],"gpt_icon":0},{"id":"2567901736","title":"Stonegate Capital Partners Begins Coverage on Provident Financial Services Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2567901736","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567901736?lang=en_us&edition=fundamental","pubTime":"2025-09-13 04:20","pubTimestamp":1757708417,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provident Financial Services Inc. published the original content used to generate this news brief via Newsfile  on September 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL9QH0yL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2567903168","title":"Director John Pugliese Reports Disposal of Common Shares in Provident Financial Services Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2567903168","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567903168?lang=en_us&edition=fundamental","pubTime":"2025-09-13 00:23","pubTimestamp":1757694235,"startTime":"0","endTime":"0","summary":"John Pugliese, a director of Provident Financial Services Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provident Financial Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDLb5LGfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2566947754","title":"Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig","url":"https://stock-news.laohu8.com/highlight/detail?id=2566947754","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566947754?lang=en_us&edition=fundamental","pubTime":"2025-09-12 12:39","pubTimestamp":1757651940,"startTime":"0","endTime":"0","summary":"NANJING, China, Sept. 12, 2025 /PRNewswire/ -- Nanjing LeadsBiolabs Co., Ltd.  today announced the first patient has been successfully dosed in a Phase 1b/II clinical trial  evaluating Opamtistomig  as monotherapy or in combination with other agents for the first-line treatment of advanced melanoma.Opamtistomig, a uniquely designed PD-L1/4-1BB bispecific antibody that simultaneously blocks PD-1/L1-mediated immune suppression and enhances 4-1BB-regulated T-cell activation. This dual mechanism has the potential to convert \"cold tumors\" into \"hot tumors\", overcoming resistance to immunotherapy and improving response rates in hard-to-treat cancers.In two prior clinical trials, Opamtistomig demonstrated promising efficacy and a favorable safety profile in patients with highly malignant, immune-cold extrapulmonary neuroendocrine carcinoma , both as monotherapy and in combination with chemotherapy. Notably, patient enrollment was completed in August 2025 for a pivotal single-arm registration ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/indication-expansion-accelerates-first-patient-dosed-in-melanoma-phase-1bii-trial-of-opamtistomig-302554832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF417.EUR","BK4195","BTC.AU","LU0868494617.USD","LU2298321311.HKD","LU1974910355.USD","IE0009354923.USD","ORR","LU2092937221.SGD","IE00B3CCJ633.GBP","LU2106854487.HKD","ORR.AU","BK4086","IE00B2PGVK34.USD","OC","BK7095","LU2041044095.USD","LU1917777945.USD","LU2023250504.SGD","LU2360108059.USD","LU2048586759.USD","BTC","BK4183","BK4211","LU2023250843.SGD","ODD","HCC","BK4006","PFS"],"gpt_icon":0},{"id":"2566944798","title":"Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2566944798","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566944798?lang=en_us&edition=fundamental","pubTime":"2025-09-12 11:00","pubTimestamp":1757646000,"startTime":"0","endTime":"0","summary":"Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more than one year. First and only chemotherapy-free combination in the first line setting to show survival improvement of this magnitude in a population with the highest-prevalence of EGFR-mutated lung cancer. \"Overall survival is the most meaningful measure of progress, and the MARIPOSA Asia cohort results reinforce the role of therapeutic innovations like amivantamab plus lazertinib in the first-line setting,\" said Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific. \"With its triple mode of action targeting EGFR a","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/asia-cohort-of-phase-3-mariposa-study-shows-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-achieved-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-versus-osimertinib-in-egfr-mutated--302554655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","LU0203345920.USD","BK4585","LU1221951129.SGD","LU0289739699.SGD","LU2129689431.USD","IE00BVYPNV92.GBP","IE00BJJMRZ35.SGD","LU1066051498.USD","IE000M9KFDE8.USD","LU1280957306.USD","LU0345769631.USD","LU1061106388.HKD","LU2133065610.SGD","PFS","LU1261432733.SGD","LU2430703178.SGD","LU1162221912.USD","IE00B19Z3581.USD","IE00B42XCP33.USD","LU1244550221.USD","LU0345769128.USD","LU0320765646.SGD","IE00BSNM7G36.USD","LU1894683348.USD","LU1267930813.SGD","ORR.AU","LU2129689605.HKD","BK4550","BK4592","LU2471134879.HKD","LU0985320562.USD","IE0002270589.USD","JNJ","LU0058720904.USD","OS","ORR","SEER","LU1732800096.USD","IE00BBT3K403.USD","BK4121","BK4195","IE0002141913.USD","IE00B4R5TH58.HKD","LU0640476718.USD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU1718418525.SGD","LU1032466523.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2566949975","title":"The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2566949975","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566949975?lang=en_us&edition=fundamental","pubTime":"2025-09-12 09:51","pubTimestamp":1757641860,"startTime":"0","endTime":"0","summary":"SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology  announced that the New Drug Application  for anbenitamab injection , independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. , has been accepted by the National Medical Products Administration . KN026 has been applied for as a Class 1 therapeutic biological product and the indication is for use in combination with chemotherapy for the treatment of patients with HER2-positive locally advanced, recurrent, or metastatic gastric or gastroesophageal junction cancer who have failed at least one prior systemic therapy .Currently, there are no approved anti-HER2 therapies for the second-line treatment of HER2-positive gastric cancer. KN026 is the first HER2 bispecific antibody to demonstrate positive results in the second-line treatment of gastric cancer in China. Meanwhile, multiple pivotal Phase III clinical studies of KN026 in g","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/the-new-drug-application-for-kn026-anbenitamab-injection-has-been-accepted-by-the-national-medical-products-administration-302554598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","LU0053666078.USD","LU1223082196.USD","BK4097","BK4017","LU1223082519.USD","CDE","BK7050","OS","BK7095","BK4588","BK4190","BK4211","ORR.AU","NHLD","LU2487616109.SGD","BC","BK4107","BK4195","BK4585","LU0210528500.USD","PFS","L","CDE.AU","LU1223083913.SGD"],"gpt_icon":0},{"id":"2566914940","title":"Centerra Gold’s Mount Milligan PFS Outlines Mine Life to 2045, Delivering Growth with a Fully Funded, Disciplined $186 Million Growth Capital Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2566914940","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566914940?lang=en_us&edition=fundamental","pubTime":"2025-09-12 05:00","pubTimestamp":1757624400,"startTime":"0","endTime":"0","summary":"This news release contains forward-looking information about expected future events that is subject to risks and assumptions set out in the “Cautionary Statement on Forward-Looking Information” below.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/11/3148925/0/en/Centerra-Gold-s-Mount-Milligan-PFS-Outlines-Mine-Life-to-2045-Delivering-Growth-with-a-Fully-Funded-Disciplined-186-Million-Growth-Capital-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0788108826.HKD","LU0130102774.USD","LU0980610538.SGD","LU2417539215.USD","LU1244550221.USD","LU2360032135.SGD","LU0345780521.USD","BK4566","LU1162221912.USD","A","LU0724618789.USD","LU2456880835.USD","BK4195","LU2125154935.USD","BK4559","BK4534","LU1244550577.SGD","LU0072461881.USD","LU0320765646.SGD","LU0496367417.USD","B","LU2229751404.USD","LU0345780281.USD","LU0498741114.HKD","BK4570","BK4207","LU1244550494.USD","BK4121","LU2089279066.USD","IE00BSNM7G36.USD","LU2413666699.HKD","LU0130517989.USD","LU0498741890.SGD","LU1201861249.SGD","IE00BN0W2T93.GBP","LU0648001328.SGD","LU0477156953.USD","LU0052756011.USD","IE00BN0W2V16.EUR","LU0347712357.USD","LU1668664300.SGD","PFS","CGAU","BK4585","LU2413666426.HKD","LU0170899867.USD","BK4211","LU0128525689.USD","LU1721428933.USD","BK4504"],"gpt_icon":0},{"id":"2566499922","title":"MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2566499922","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566499922?lang=en_us&edition=fundamental","pubTime":"2025-09-11 21:27","pubTimestamp":1757597220,"startTime":"0","endTime":"0","summary":"CHICAGO, Sept.  11, 2025  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunoth","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/11/3148625/0/en/MAIA-Biotechnology-Highlights-Positive-Efficacy-Data-from-THIO-101-Phase-2-Clinical-Trial-in-Non-Small-Cell-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","CPI","BK4195","IE00BSNM7G36.USD","BK4107","BK4588","MAIA","LU0210528500.USD","BK4139","BK4196","LU0053666078.USD","LU0058720904.USD","ORR","LU2487616109.SGD","BK4585","LU0868494617.USD","OS","PFS","L","LU0289739699.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU1059921491.USD","CI","IE00B19Z3B42.SGD","LU1261432733.SGD","BK4097"],"gpt_icon":0},{"id":"2566561739","title":"Press Release: Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2566561739","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566561739?lang=en_us&edition=fundamental","pubTime":"2025-09-11 14:00","pubTimestamp":1757570400,"startTime":"0","endTime":"0","summary":"NOTTINGHAM, United Kingdom, Sept. 11, 2025  -- Scancell Holdings plc , the developer of ImmunoBody and Moditope active immunotherapies to treat cancer, today announces a business update and provides its final audited financial results for the year ended 30 April 2025.-- Positive data reported from Phase 2 SCOPE trial shows iSCIB1+ in. combination with checkpoint inhibitors has the potential to set the new. -- Progression-free survival  for iSCIB1+ in the target HLA population. at 11 months is 78% comparing favourably against historic 12 month PFS of. 46% reported by doublet checkpoint therapy of ipilimumab and nivolumab 1. -- Combined data for the defined human leukocyte antigen  target. population across Cohorts 1 and 3 shows 22 month PFS of 69%, representing. a meaningful improvement over historic doublet checkpoint therapy. -- Overall response rate  and disease control rate  for SCIB1 and. iSCIB1+ also demonstrates superiority whether combined with doublet. -- iSCIB1+ selected for f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4142","IE00BD0PCF45.HKD","BK4195","BK4232","BK4211","BK4156","BK4022","IE00B45NX917.SGD","IE00B95QR487.USD","LU1718418525.SGD","ORR","R","MAR","BK4588","IE00B1G9WX41.USD","PFS","BK4585","IE00B0T0GQ85.USD"],"gpt_icon":0},{"id":"2566598401","title":"Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2566598401","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566598401?lang=en_us&edition=fundamental","pubTime":"2025-09-11 04:02","pubTimestamp":1757534520,"startTime":"0","endTime":"0","summary":"Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial clinic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/10/3148221/0/en/Revolution-Medicines-Shares-New-Clinical-Results-Supporting-Initiation-of-RASolute-303-a-Global-Phase-3-Registrational-Trial-of-Daraxonrasib-in-First-Line-Metastatic-Pancreatic-Duc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU1059921491.USD","BK4213","BK4166","ET","LU1978683503.SGD","BK4195","LU1861219969.SGD","BK4588","LU1854104046.USD","LU2360107325.USD","LU1861220033.SGD","LU1854103824.USD","BK4561","RVMD","BK4144","ON","IE00B19Z3B42.SGD","BK4590","IE00BZ199S13.USD","BK4585","LU2298322129.HKD","IE00BSNM7G36.USD","LU0348723411.USD","PFS","BK4139","BK4605","IE0002270589.USD","BK4581","OS","QD","LU0124384867.USD","LU0266512127.USD","IE00BD6J9T35.USD","BK4211","LU1720051108.HKD","BK4512","LU2357305700.SGD","LU0289739699.SGD","CI","LU1720051017.SGD","CRC","LU1861215975.USD","BK4141","LU0868494617.USD","ORR","LU0456854461.SGD","LU1261432733.SGD","LU1548497426.USD","MDCO"],"gpt_icon":0},{"id":"2566461037","title":"Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2566461037","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566461037?lang=en_us&edition=fundamental","pubTime":"2025-09-10 03:10","pubTimestamp":1757445000,"startTime":"0","endTime":"0","summary":"Libtayo plus chemotherapy showed superior survival and response rates over five years in advanced NSCLC patients without EGFR, ALK, or ROS1 mutations.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/09/Tarrytown--Ny---March-21--2020---This-We.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/09/Tarrytown--Ny---March-21--2020---This-We.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/09/47580767/regenerons-libtayo-combo-achieves-nearly-double-survival-rate-in-advanced-lung-cancer-compared-to-chemotherapy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/09/47580767/regenerons-libtayo-combo-achieves-nearly-double-survival-rate-in-advanced-lung-cancer-compared-to-chemotherapy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IE00B7SZL793.SGD","BK4195","BK4211","IE00B19Z4B17.USD","OS","ORR","BK4157","IE0031619046.USD","IE00B66KJ199.SGD","PFS","AEIS","BK4097"],"gpt_icon":0},{"id":"2565468022","title":"YY Group Announces Highlights of the Company’s Preliminary First Half 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2565468022","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565468022?lang=en_us&edition=fundamental","pubTime":"2025-09-08 22:53","pubTimestamp":1757343180,"startTime":"0","endTime":"0","summary":"The Company’s preliminary data shows an increase in gross profit by nearly 100% and full-year 2025 revenue is projected to exceed $60 millionSingapore , Sept.  08, 2025  (GLOBE NEWSWIRE) -- YY Group H","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/08/3146261/0/en/YY-Group-Announces-Highlights-of-the-Company-s-Preliminary-First-Half-2025-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4551","PFS","BK4503","BK4535","API","BK4211","BK4023"],"gpt_icon":0},{"id":"2565756379","title":"MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2565756379","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565756379?lang=en_us&edition=fundamental","pubTime":"2025-09-05 21:03","pubTimestamp":1757077380,"startTime":"0","endTime":"0","summary":"Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept.  05, 2025  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/05/3145282/0/en/MAIA-Biotechnology-Abstract-Selected-for-Poster-Presentation-at-2025-IASLC-World-Conference-on-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4107","CPI","ORR","LU2487616109.SGD","MAIA","PFS","LU1261432733.SGD","BK4588","LU0210528500.USD","LU0868494617.USD","LU0058720904.USD","BK4211","LU0289739699.SGD","BK4585","BK4196","LU0053666078.USD","BK4195","BK4097","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU1059921491.USD","IE00B19Z3581.USD","L","BK4139","CI","IE0002270589.USD"],"gpt_icon":0},{"id":"2564580582","title":"McEwen Reports Attractive Gold Intercepts at Grey Fox; Results Support Resource Growth Ahead of Upcoming Resource Estimate; Gibson: 10.1 g/t Gold Over 5.8 m (25GF-1597) and 10.4 g/t Gold Over 5.6 m (25GF-1564), GFS: 4.8 g/t Gold Over 14.9 m (25GF-1575)","url":"https://stock-news.laohu8.com/highlight/detail?id=2564580582","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564580582?lang=en_us&edition=fundamental","pubTime":"2025-09-02 18:00","pubTimestamp":1756807200,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  02, 2025  (GLOBE NEWSWIRE) -- McEwen Inc. (NYSE: MUX) (TSX: MUX) (“McEwen”, \"MUX\") is pleased to report that drilling at FoxComplex’s GreyFox Project continues to deliver attractive go","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3142432/37420/en/McEwen-Reports-Attractive-Gold-Intercepts-at-Grey-Fox-Results-Support-Resource-Growth-Ahead-of-Upcoming-Resource-Estimate-Gibson-10-1-g-t-Gold-Over-5-8-m-25GF-1597-and-10-4-g-t-Gol.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","LU0354030438.USD","BK4112","BK4588","GFS","BK4585","LU0353189680.USD","LU0353189763.USD","BK4017","NYSE","LU0077335932.USD","MUX","LU0417517546.SGD","BK4195","LU0054578231.USD","LU2543165471.USD","LU0256863811.USD","BK4605","LU0354030511.USD","PFS","LU2087625088.SGD","CW","TW","BK4211","BK4187"],"gpt_icon":0},{"id":"2563079024","title":"BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2563079024","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563079024?lang=en_us&edition=fundamental","pubTime":"2025-08-29 22:16","pubTimestamp":1756476960,"startTime":"0","endTime":"0","summary":"BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/29/Medical-researcher.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/29/Medical-researcher.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/08/47414435/beone-medicines-stock-gains-momentum-with-early-stage-trial-success-for-pretreated-lymphoma-patients","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/08/47414435/beone-medicines-stock-gains-momentum-with-early-stage-trial-success-for-pretreated-lymphoma-patients","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4161","PFS","MDCO","ORR","BK4017","LU1223082519.USD","BK4211","CDE","LU1223083913.SGD","CR","LU1223082196.USD","BK4195","SSI"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":118,"code":"91000000","status":"200"}]}}